However, I have had contact today from the Association of the British Pharmaceutical Industry, which feels that a key question that was raised in our letter of 2 March has not yet been addressed—namely, how do the area drug and therapeutics committees appraise which medicines are deemed equivalent, and how do we ensure that there is openness and visibility around those decisions and that the equivalent medicines are named so that patients and clinicians are aware of which should be used in place of a Scottish Medicines Consortium-accepted medicine?